

Juan G. Abraldes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8819036/publications.pdf>

Version: 2024-02-01

142
papers

17,003
citations

16411

64
h-index

14702

127
g-index

148
all docs

148
docs citations

148
times ranked

10492
citing authors

#	ARTICLE	IF	CITATIONS
1	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. <i>Hepatology</i> , 2017, 65, 310-335.	3.6	1,520
2	Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. <i>New England Journal of Medicine</i> , 2010, 362, 2370-2379.	13.9	1,075
3	The clinical use of HVPG measurements in chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 573-582.	8.2	576
4	Liver cirrhosis. <i>Lancet, The</i> , 2021, 398, 1359-1376.	6.3	515
5	Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: Results of a randomized study. <i>Gastroenterology</i> , 2004, 126, 469-475.	0.6	468
6	Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. <i>Hepatology</i> , 2003, 37, 902-908.	3.6	456
7	Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 102-111.e1.	0.6	437
8	Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 776-783.	2.4	407
9	β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2019, 393, 1597-1608.	6.3	375
10	Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2009, 136, 1651-1658.	0.6	372
11	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	0.6	353
12	Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. <i>Hepatology</i> , 2008, 48, 442-448.	3.6	351
13	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. <i>Gastroenterology</i> , 2014, 146, 412-419.e3.	0.6	285
14	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. <i>Journal of Hepatology</i> , 2008, 48, 229-236.	1.8	284
15	Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. <i>Hepatology</i> , 2013, 58, 1824-1835.	3.6	269
16	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2747-2756.	0.2	268
17	Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study. <i>Journal of Hepatology</i> , 2013, 58, 45-50.	1.8	259
18	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. <i>Gastroenterology</i> , 2004, 126, 749-755.	0.6	258

#	ARTICLE	IF	CITATIONS
19	The management of portal hypertension: Rational basis, available treatments and future options. <i>Journal of Hepatology</i> , 2008, 48, S68-S92.	1.8	248
20	Current management of portal hypertension. <i>Journal of Hepatology</i> , 2003, 38, 54-68.	1.8	245
21	Good long-term outcome of Budd-Chiari syndrome with a step-wise management. <i>Hepatology</i> , 2013, 57, 1962-1968.	3.6	237
22	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 1160-1170.e3.	0.6	232
23	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015, 62, 762-772.	3.6	230
24	Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. <i>American Journal of Gastroenterology</i> , 2006, 101, 506-512.	0.2	228
25	Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. <i>Journal of Hepatology</i> , 2007, 46, 1040-1046.	1.8	203
26	Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. <i>Journal of Clinical Investigation</i> , 2012, 122, 368-382.	3.9	183
27	Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2006, 26, 348-362.	1.8	182
28	Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2010, 52, 2044-2052.	3.6	180
29	Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD. <i>PLoS ONE</i> , 2012, 7, e32785.	1.1	180
30	Eight Weeks of Exercise Training Increases Aerobic Capacity and Muscle Mass and Reduces Fatigue in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1920-1926.e2.	2.4	180
31	Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension. <i>Journal of Hepatology</i> , 2010, 53, 558-567.	1.8	178
32	Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G980-G987.	1.6	176
33	Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1412-1417.	2.4	175
34	A Model to Identify Sarcopenia in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1473-1480.e3.	2.4	175
35	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	0.6	162
36	KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. <i>Gut</i> , 2015, 64, 1434-1443.	6.1	159

#	ARTICLE	IF	CITATIONS
37	A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale. <i>American Journal of Gastroenterology</i> , 2016, 111, 1759-1767.	0.2	152
38	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012, 56, 103-108.	1.8	142
39	Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. <i>Gut</i> , 2011, 60, 1133-1138.	6.1	141
40	Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1159-1167.	0.2	131
41	Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. <i>Hepatology</i> , 2003, 37, 172-181.	3.6	126
42	Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , 2009, 51, 279-287.	1.8	116
43	Portal Hypertension. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S125-S130.	1.1	115
44	Portal Hypertension and Gastrointestinal Bleeding. <i>Seminars in Liver Disease</i> , 2008, 28, 003-025.	1.8	114
45	Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. <i>Journal of Hepatology</i> , 2010, 52, 846-853.	1.8	114
46	Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. <i>Digestive and Liver Disease</i> , 2012, 44, 855-860.	0.4	113
47	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	3.6	113
48	Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2010, 53, 273-282.	1.8	112
49	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	1.8	112
50	Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension. <i>PLoS ONE</i> , 2013, 8, e58742.	1.1	110
51	Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 2006, 43, 485-491.	3.6	106
52	Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. <i>Liver International</i> , 2019, 39, 1437-1447.	1.9	91
53	Home Exercise Training Improves Exercise Capacity in Cirrhosis Patients: Role of Exercise Adherence. <i>Scientific Reports</i> , 2018, 8, 99.	1.6	89
54	Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. <i>Hepatology</i> , 2010, 52, 1783-1790.	3.6	88

#	ARTICLE	IF	CITATIONS
55	Portal cholangiopathy: radiological classification and natural history. <i>Gut</i> , 2011, 60, 853-860.	6.1	88
56	Somatostatin and analogues in portal hypertension. <i>Hepatology</i> , 2002, 35, 1305-1312.	3.6	87
57	Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. <i>Hepatology</i> , 2013, 57, 1172-1181.	3.6	84
58	Cirrhosis as new indication for statins. <i>Gut</i> , 2020, 69, 953-962.	6.1	81
59	Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G147-G156.	1.6	79
60	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. <i>Hepatology</i> , 2003, 37, 378-384.	3.6	78
61	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	3.7	75
62	Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study. <i>Hepatology</i> , 2010, 51, 2108-2116.	3.6	74
63	Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2003, 39, 515-521.	1.8	68
64	Characterization of $\beta 1$ T cell subsets in organ transplantation. <i>Transplant International</i> , 2010, 23, 1045-1055.	0.8	68
65	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	3.6	67
66	Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. <i>Liver Transplantation</i> , 2010, 16, 348-356.	1.3	65
67	Insulin resistance and liver microcirculation in a rat model of early NAFLD. <i>Journal of Hepatology</i> , 2011, 55, 1095-1102.	1.8	64
68	Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. <i>Liver International</i> , 2014, 34, 16-25.	1.9	64
69	Acute Variceal Bleeding. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 46-54.	0.8	62
70	Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care. <i>Hepatology Communications</i> , 2019, 3, 1322-1333.	2.0	61
71	Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. <i>Journal of Hepatology</i> , 2013, 58, 1140-1146.	1.8	60
72	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021, 75, 1026-1033.	1.8	59

#	ARTICLE	IF	CITATIONS
73	The Treatment of Acute Variceal Bleeding. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S312-S317.	1.1	52
74	Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 584-590.	2.2	50
75	Utility of Color Doppler Ultrasonography Predicting TIPS Dysfunction. <i>American Journal of Gastroenterology</i> , 2005, 100, 2696-2701.	0.2	49
76	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. <i>Hepatology</i> , 2013, 58, 2079-2088.	3.6	48
77	Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2006, 44, 886-893.	1.8	47
78	Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. <i>Journal of Hepatology</i> , 2018, 69, 626-634.	1.8	46
79	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. <i>Hepatology</i> , 2019, 69, 1287-1299.	3.6	45
80	Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. <i>Journal of Hepatology</i> , 2011, 55, 307-314.	1.8	43
81	Complications after ERCP in liver transplant recipients. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 285-294.	0.5	40
82	Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1125-1133.	1.6	40
83	Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. <i>Hepatology</i> , 2006, 43, 27-33.	3.6	39
84	Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. <i>Gastroenterology</i> , 2012, 35, 488-495.	0.2	37
85	Hypercoagulability in Patients With Chronic Noncirrhotic Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 72-78.	2.4	36
86	Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. <i>Disease Markers</i> , 2011, 31, 129-38.	0.6	36
87	Extrahepatic portal vein thrombosis in children and adolescents: Influence of genetic thrombophilic disorders. <i>World Journal of Gastroenterology</i> , 2010, 16, 6123.	1.4	33
88	The Amount of Alcohol Consumption Negatively Impacts Short-Term Mortality in Mexican Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1472-1480.	0.2	33
89	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. <i>Hepatology</i> , 2020, 72, 1353-1365.	3.6	32
90	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. <i>Hepatology</i> , 2006, 43, 34-41.	3.6	31

#	ARTICLE	IF	CITATIONS
91	Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure. <i>Liver International</i> , 2019, 39, 1271-1280.	1.9	31
92	Non-invasive alloimmune risk stratification of long-term liver transplant recipients. <i>Journal of Hepatology</i> , 2021, 75, 1409-1419.	1.8	31
93	Portal Hypertension Secondary to Myelofibrosis: A Study of Three Cases. <i>American Journal of Gastroenterology</i> , 2005, 100, 2355-2358.	0.2	30
94	Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. <i>Shock</i> , 2017, 47, 370-377.	1.0	30
95	The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. <i>Journal of Hepatology</i> , 2021, 75, S118-S134.	1.8	30
96	Nitric oxide and portal hypertension. <i>Metabolic Brain Disease</i> , 2002, 17, 311-324.	1.4	29
97	The Management of Portal Hypertension. <i>Clinics in Liver Disease</i> , 2005, 9, 685-713.	1.0	29
98	The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 226-240.	0.3	29
99	Patient-perceived barriers to lifestyle interventions in cirrhosis. <i>Saudi Journal of Gastroenterology</i> , 2017, 23, 97.	0.5	29
100	Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension. <i>American Journal of Gastroenterology</i> , 2013, 108, 926-932.	0.2	28
101	Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2013, 108, 75-82.	0.2	27
102	Patients Whose First Episode of Bleeding Occurs While Taking a β -Blocker Have High Long-term Risks of Rebleeding and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 670-676.	2.4	26
103	Insulin resistance in patients with cirrhosis and portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G1458-G1465.	1.6	23
104	Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. <i>Gastroenterology & Hepatology</i> , 2013, 36, 527-533.	0.2	23
105	Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. <i>British Journal of Haematology</i> , 2004, 124, 329-335.	1.2	22
106	Management of gastrointestinal bleeding in patients with cirrhosis of the liver. <i>Seminars in Hematology</i> , 2004, 41, 8-12.	1.8	22
107	Developments and controversies in the management of oesophageal and gastric varices. <i>Gut</i> , 2010, 59, 701-705.	6.1	22
108	Spleen stiffness: Toward a noninvasive portal sphygmomanometer?. <i>Hepatology</i> , 2013, 57, 1278-1280.	3.6	22

#	ARTICLE	IF	CITATIONS
109	Variceal Bleeding: Pharmacological Therapy. <i>Digestive Diseases</i> , 2005, 23, 18-29.	0.8	21
110	Effect of rifaximin on infections, acute and chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH). <i>Liver International</i> , 2022, 42, 1109-1120.	1.9	20
111	Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G496-G502.	1.6	19
112	A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. <i>Liver International</i> , 2015, 35, 695-703.	1.9	18
113	A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. <i>BMC Gastroenterology</i> , 2021, 21, 120.	0.8	18
114	Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. <i>Journal of Hepatology</i> , 2013, 59, 717-722.	1.8	17
115	Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients. <i>Liver Transplantation</i> , 2001, 7, 649-651.	1.3	16
116	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	1.8	16
117	Bacterial infections in acute variceal hemorrhage despite antibiotics: a multicenter study of predictors and clinical impact. <i>United European Gastroenterology Journal</i> , 2017, 5, 1090-1099.	1.6	15
118	Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. <i>Gastroenterology</i> , 2020, 159, 422-427.e1.	0.6	15
119	Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. <i>Hepatology</i> , 2020, 72, 1029-1042.	3.6	14
120	A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β_2 -Blockade in Non-Clinical Trial Patients. <i>American Journal of Gastroenterology</i> , 2010, 105, 1917-1921.	0.2	13
121	Selective arterial embolization for life threatening hemobilia after transjugular intrahepatic portosystemic shunt placement. <i>Journal of Hepatology</i> , 2001, 34, 174-176.	1.8	10
122	Decreased intrahepatic response to β_1 -adrenergic agonists in lipopolysaccharide-treated rats is located in the sinusoidal area and depends on Kupffer cell function. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 893-900.	1.4	10
123	STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?. <i>Hepatology</i> , 2016, 64, 13-15.	3.6	9
124	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study. <i>Liver Transplantation</i> , 2013, 19, 450-456.	1.3	8
125	Statins: the Panacea of Cirrhosis?. <i>Current Hepatology Reports</i> , 2016, 15, 1-7.	0.4	8
126	Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list. <i>Hepatology Communications</i> , 2022, 6, 1699-1710.	2.0	8

#	ARTICLE	IF	CITATIONS
127	Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension. <i>Journal of Hepatology</i> , 2006, 44, 1040-1045.	1.8	6
128	Large conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis. <i>Liver International</i> , 2008, 28, 566-573.	1.9	6
129	Association between gut colonization of vancomycin-resistant enterococci and liver transplant outcomes. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	6
130	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	2.0	5
131	Novel approaches to treat portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S232-S241.	1.4	3
132	Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000798.	1.1	3
133	Lack of Correlation Between Preoperative and Intraoperative Liver Hemodynamics. <i>Transplantation</i> , 2014, 97, 116-121.	0.5	2
134	Can We Add the History of the Nonoperative Therapy of Varices to Other Success Chapters of Modern Medicine?. <i>Clinical Liver Disease</i> , 2020, 16, 73-82.	1.0	2
135	Royal Free Hospital-estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. <i>Liver International</i> , 2021, 41, 819-827.	1.9	2
136	Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?. <i>Journal of Hepatology</i> , 2021, 75, 750-752.	1.8	2
137	Editorial: is there a causal link between non-selective beta blockers and portal vein thrombosis in cirrhosis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 819-820.	1.9	1
138	Classifying varices in cirrhosis: Who's got the best look?. <i>Liver International</i> , 2020, 40, 754-755.	1.9	1
139	An uncommon cause of massive scrotal enlargement. <i>Liver International</i> , 2010, 30, 995-995.	1.9	0
140	Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2017-2021.	1.6	0
141	Reply. <i>Gastroenterology</i> , 2016, 151, 1037-1038.	0.6	0
142	Issues in Trial Design and Areas Needing Further Research. , 2016, , 355-363.		0